美国乳腺癌辅助内分泌治疗实施质量评估
该回顾性队列研究纳入国家癌症数据库2004年1月1日至2013年12月31日981729例乳腺癌女性,评估辅助内分泌治疗(AET)实施的时间趋势及相关因素。激素受体阳性(HR+)患者AET接受率从2004年69.8%升至2013年82.4%,HR-患者从5.2%降至3.4%。AET与死亡风险相对降低29%相关;若全部HR+患者接受AET,10年约可挽救14630例生命。
要点
- HR+乳腺癌患者AET接受率从2004年69.8%升至2013年82.4%,HR-患者从5.2%降至3.4%。
- 医院层面依从率(≥80%的HR+患者接受AET)从2004年40.2%升至2013年69.2%。
- AET与死亡风险相对降低29%相关;若全部HR+患者接受AET,10年约可挽救14630例生命。
核心结论
- 2004年至2013年,乳腺癌患者AET的使用不足与误用有所减少,但最佳使用尚未实现,且诊疗仍存在显著差异。
- 手术与放疗是AET最佳使用最显著的相关因素之一,凸显团队协作支持指南一致性治疗的价值。
研究设计与样本
- 回顾性队列研究,纳入国家癌症数据库2004年1月1日至2013年12月31日981729例乳腺癌女性,均为I至III期且在报告机构接受全部或部分治疗。
- 患者平均(标准差)年龄60.8(13.3)岁;其中818435例为HR+,163294例为HR-。
主要发现
- HR+患者AET接受率从2004年69.8%升至2013年82.4%;HR-患者从2004年5.2%降至2013年3.4%。
- 医院层面依从率(≥80%的HR+患者接受AET)从2004年40.2%升至2013年69.2%。
- AET接受率随年龄(≥80岁患者较低)、种族(非洲裔美国人与西班牙裔参与者较低)、地理位置(West South Central、Mountain与Pacific普查区域较低)及受体状态(雌激素受体阴性且孕激素受体阳性患者较低)而显著不同。
- 手术与放疗是与适当AET接受最显著相关的因素,仅接受肿块切除术而未接受放疗的患者中AET接受率仅为45.0%。
- AET接受与死亡风险相对降低29%相关;基于该有效性估计,若全部HR+患者接受AET,10年约可挽救14630例生命。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Randomized trials in breast cancer have demonstrated the clinical benefits of adjuvant endocrine therapy (AET) in preventing recurrence and death. The examination of concordance with AET guidelines at a national level as a measure of quality of care is important. OBJECTIVE: To investigate temporal trends and factors related to receipt of AET for breast cancer. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included 981 729 women with breast cancer in the National Cancer Database from January 1, 2004, to December 31, 2013. Women with stages I to III breast cancer who received all or part of their treatment at the reporting institution were included in the analysis. MAIN OUTCOMES AND MEASURES: Temporal changes in AET receipt (estimating the annual percentage change) and AET practice patterns (using logistic regression) and the effect of AET guideline concordance on survival of women with hormone receptor-positive (HR+) breast cancer (using the multivariable Cox proportional hazards model). RESULTS: Of the 981 729 eligible patients (mean [SD] age, 60.8 [13.3] years), 818 435 had HR+ and 163 294 had HR-negative (HR-) cancer. Among the patients with HR+ cancer, receipt of AET increased over time, from 69.8% in 2004 to 82.4% in 2013. Among patients with HR- cancer, receipt decreased from 5.2% in 2004 to 3.4% in 2013. Hospital-level adherence (≥80% of patients with HR+ cancer received AET) increased from 40.2% in 2004 to 69.2% in 2013. Receipt of AET varied significantly by age (lower in patients ≥80 years), race (lower in African American and Hispanic participants), geographic location (lower in West South Central, Mountain, and Pacific census regions), and receptor status (lower in patients with estrogen receptor-negative and progesterone receptor-positive cancer). Surgery and radiotherapy were the factors most significantly associated with appropriate AET receipt (only 45.0% in patients who received lumpectomy without radiotherapy). Receipt of AET was associated with a 29% relative risk reduction in mortality. Based on this effectiveness estimate, if all patients with HR+ cancer received AET, approximately 14 630 lives would have been saved over 10 years. CONCLUSIONS AND RELEVANCE: From 2004 to 2013, underuse and misuse of AET have decreased for patients with breast cancer, but optimal use has not been achieved, and significant variation in care remains. The involvement of surgery and radiotherapy were among the most significant factors associated with optimal use, which underscores the benefits of team-based care to support guideline-concordant therapy.
引用
- Daly B, Olopade OI, Hou N, et al. Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States. JAMA Oncol. 2017. PMID: 28152150. doi:10.1001/jamaoncol.2016.6380
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。